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ABSTRACT
Purpose: We assessed the temporal pattern of 29 immune and inflammatory proteins in post-acute
coronary syndrome (ACS) patients, prior to the development of recurrent ACS.
Methods: High-frequency blood sampling was performed in 844 patients admitted for ACS during
one-year follow-up. We conducted a case-control study on the 45 patients who experienced reACS
(cases) and two matched event-free patients (controls) per case. Olink Proteomics’ immunoassay was
used to obtain serum levels of the 29 proteins, expressed in an arbitrary unit on the log2-scale
(Normalized Protein eXpression, NPX). Linear mixed-effects models were applied to examine the tem-
poral pattern of the proteins, and to illustrate differences between cases and controls.
Results: Mean age was 66±12 years and 80% were men. Cases and controls had similar baseline clinical
characteristics. During the first 30 days, and after multiple testing correction, cases had significantly higher
serum levels of CXCL1 (difference of 1.00 NPX, p¼ 0.002), CD84 (difference of 0.64 NPX, p¼ 0.002) and
TNFRSF10A (difference of 0.41 NPX, p< 0.001) than controls. After 30 days, serum levels of all 29 proteins
were similar in cases and controls. In particular, no increase was observed prior to reACS.
Conclusions: Among 29 immune and inflammatory proteins, CXCL1, CD84 and TNFRSF10A were asso-
ciated with early reACS after initial ACS-admission.
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Introduction
In the pathophysiology of atherosclerosis, the lipid metabolism
and the immune and inflammatory systems are interconnected
(Libby et al. 2009, 2011). It is known that both lipids and inflam-
matory biomarkers are affected by LDL lowering treatment,
which importantly reduces the occurrence of cardiovascular
events. However, despite adequately lowering LDL levels, a
considerable number of patients with CVD will still develop
adverse (coronary) events, especially those with a residual
inflammatory risk (Libby 2005). Therefore, more insights in the
role of the immune- and inflammatory systems are required.
The research field of proteomics offers a novel way to gain
understanding of disease processes (Miller et al. 2007). As the
proteome is considered the end product of the genome, and has
a regulatory role in all kinds of biological processes in the human
body, proteins are fundamental to determine onset and
progression of diseases, including CVD. The advantage of
research on proteins is the direct information it may offer at tissue
level, regardless of a patient’s genotype. Novel technologies are
emerging to simultaneously detect expression patterns of mul-
tiple proteins. These technologies offer the opportunity to assess
expression patterns of proteins belonging to several pathophysio-
logical pathways simultaneously (Assarsson et al. 2014).
Studying the temporal behaviour of the proteome in
patients with CVD prior to a recurrent coronary event may
potentially lead to the identification of proteins related to
progression of atherosclerosis. Therefore, we performed a
controlled prospective study to assess the temporal pattern
of a wide range of proteins involved in the immune- and
inflammatory systems just prior to the recurrence of a coron-
ary event during one year follow-up of patients admitted
with an acute coronary syndrome (ACS).
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Clinical significance
 Studying the behaviour over time of the proteome
involved in patients with ACS prior to a recurrent coron-
ary event may lead to the identification of proteins
related to progression of pathological atherogenesis.
 Our exploratory study shows that an ACS may trigger
short-term upregulation of CXCL1, CD84 and TNFRSF10A
which might play a role in the development of early
recurrent coronary events.
 Further research, including in vitro studies, are warranted to
unravel the potential mechanisms underlying our findings.
Methods
Study population
The ‘BIOMarker study to identify the Acute risk of a Coronary
Syndrome’ (BIOMArCS) is a multicentre observational study
with a design characterized by high-frequent blood sampling
to assess the course over time of blood biomarkers during
one-year follow-up of patients who have been admitted with
an ACS, and to study the temporal pattern of these bio-
markers just prior to the occurrence of an imminent repeat
coronary event (Oemrawsingh et al. 2016). In brief, patients
aged 40 years, who were admitted with an ACS, and who
had 1 cardiovascular risk factor were eligible. The diagnosis
ACS was based on typical ischemic chest pain, lasting
>10min in the preceding 24 h, in combination with objective
evidence of myocardial necrosis, as obtained from the ECG
(ST-segment elevation or dynamic ST-segment depression) or
biochemistry (CKMB or cardiac troponin elevation). After
enrolment, venepunctures were performed every two weeks
during the first six months and every four weeks during the
second six months of follow-up.
BIOMArCS was approved by the Institutional Review Boards
of all 18 enrolling hospitals, and all participating patients pro-
vided written informed consent. BIOMArCS is registered in The
Netherlands Trial Register NTR1698 and NTR1106.
Figure 1. Patient flow diagram. BIOMArCS: BIOMarker study to identify the Acute risk of a Coronary Syndrome; ACS: acute coronary syndrome.
Table 1. Overview of the immune and inflammatory protein biomarkers.
Abbreviation Full name Synonyms Molecular function
ADAM-TS13 A disintegrin and metalloproteinase with thrombospondin motifs 13 C9orf8, vWF-CP Hydrolase
ADM Adrenomedullin AM Hormone
ACE2 Angiotensin I converting enzyme 2 Peptidyl-dipeptidase A Hydrolase/receptor
CXCL1 C-X-C motif chemokine ligand 1 GRO1, GROa, MGSA, FSP, NAP-3 Chemokine/growth factor
CEACAM8 Carcinoembryonic antigen-related cell adhesion molecule 8 CGM6, CD66b Protein binding
CTSL1 Cathepsin L1 Hydrolase
HO-1 Heme oxygenase (decycling) 1 HMOX1 Oxidoreductase
IL-1ra Interleukin-1 receptor antagonist IL1RN, IRAP, ICL-1RA Cytokine
IL1RL2 Interleukin-1 receptor-like 2 IL1RRP2, IL36R Receptor
IL-17D Interleukin-17D ? To do Cytokine
IL-27 Interleukin-27 subunit alpha and beta IL27A, EBI3, IL27B Cytokine
IL-4RA Interleukin-4 receptor subunit alpha IL4R Receptor
LOX-1 Lectin-like oxidized LDL receptor 1 OLR1, CLEC8A Receptor
LPL Lipoprotein lipase LIPD Hydrolase
IgG Fc receptor II-b Fc fragment of IgG, low affinity IIb receptor FCGR2B, CD32B Receptor
MARCO Macrophage receptor with collagenous structure SCARA2 Receptor
hOSCAR Osteoclast associated, immunoglobulin-like receptor OSCAR Receptor
PTX3 Pentraxin 3 TSG14, TNFAIP5 Receptor
PIgR Polymeric immunoglobulin receptor Receptor
IL16 Pro-interleukin-16 LCF Cytokine
PD-L2 Programmed cell death 1 ligand 2 PDCD1LG2, B7DC, CD273 Receptor
RAGE Advanced glycosylation end product-specific receptor AGER Receptor
CD84 SLAM family member 5 SLAMF5 Receptor
SPON2 Spondin-2 Mindin, DIL1 Antigen binding
CD4 T-cell surface glycoprotein CD4 Antigen binding
TF Coagulation factor III (tissue factor) F3, thromboplastin Receptor
TRAIL-R2 TNF-related apoptosis-inducing ligand receptor 2 TNFRSF10B, CD262, DR5 Receptor
TNFRSF10A Tumour necrosis factor receptor superfamily member 10A CD261, DR4, TRAILR-1, APO2 Receptor
TNFRSF13B Tumour necrosis factor receptor superfamily member 13B CD267, TACI Receptor
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Case-control design
For the current study, we applied a nested case-control
design for protein measurements and statistical analysis
(Figure 1). A total of 45 patients (cases) developed the pri-
mary study endpoint composed of cardiac death, non-fatal
myocardial infarction (MI), or unstable angina (UA) requiring
urgent coronary revascularization during one year of follow-
up after the initial ACS. Each case was assigned to two con-
trols matched on age, gender and admitted hospital. For rea-
sons of efficiency, for each case, the blood sample at
hospital admission and the last two samples prior to the
recurrent endpoint event were selected. For matched con-
trols, the blood sample at hospital admission and the blood
sample that corresponds in time from enrolment with the
timing of the case-event were selected.
We were interested in the temporal patterns of the pro-
teins during the acute phase after the initial ACS (first
30 days), as well as during the stable phase after the initial
ACS (30-day to 1-year time period). Thus, separate analyses
were conducted for cases (and their matching controls) who
experienced the event in the first 30 days of follow-up after
the initial ACS, and for cases (and their matching controls)
who experienced their event thereafter until one-year
follow-up.
Protein measurements
Olink’s high throughput Proximity Extension Assay (PEA)
technique (Olink Proteomics AB, Uppsala, Sweden) was
used to measure 29 immune and inflammatory proteins of
the cardiovascular II panel (Table 1) (Assarsson et al. 2014).
Detailed information on PEA Technique is available on
Olink’s website (www.olink.com). In brief, PEA technique
allows for efficient quantification of multiple protein
biomarkers simultaneously. Every measured protein is
expressed in an arbitrary unit on the log2-scale called
Normalized Protein eXpression (NPX). Hence, an increase or
decrease of one NPX corresponds to a doubling or halving
of the protein’s serum level, respectively. To determine
approximate serum concentrations, general calibrator curves
are available on the website of Olink for each pro-
tein biomarker.
Statistical analysis
Continuous baseline characteristics are presented as medians
with 25th and 75th percentile, and were compared between
Table 2. Baseline clinical characteristics of the patients.
Cases Controls
n¼ 44 n¼ 87 p Value
Presentation and initial treatment
Men 35 (79.5) 70 (80.5) 0.90
Age (years) 67.5 (57.3–77.5) 66.7 (57.4–75.5) 0.83
Admission diagnosis 0.38
STEMI 16 (36.4) 42 (48.3)
NSTEMI 22 (50.0) 33 (37.9)
UAP 6 (13.6) 12 (13.8)
CAG performed 39 (88.6) 82 (94.3) 0.25
PCI performed 33 (86.8) 67 (81.7) 0.48
CKmax (U/L) 418 (195–1142) 513 (169–1332) 0.94
Cardiovascular risk factors
Smoking 0.81
Current 17 (38.6) 35 (40.2)
Former 12 (27.3) 27 (31.0)
Never 15 (34.1) 25 (28.7)
Diabetes mellitus 16 (36.4) 32 (36.8) 0.96
Hypertension 21 (47.7) 44 (50.6) 0.76
Hypercholesterolemia 19 (43.2) 46 (52.9) 0.30
Creatinine (mmol/L) 88 (73–93) 81 (67–97) 0.15
Cardiovascular history
Peripheral arterial disease 10 (22.7) 7 (8.0) 0.018
Myocardial infarction 14 (31.8) 33 (37.9) 0.49
PCI 14 (31.8) 29 (33.3) 0.86
CABG 10 (22.7) 17 (19.5) 0.67
Stroke 9 (20.5) 5 (5.7) 0.010
Valvular heart disease 4 (9.1) 3 (3.4) 0.18
Heart failure 4(9.1) 1 (1.1) 0.025
Medication at first blood sample moment >7 days after the index ACSa
Aspirin 35 (92.1) 76 (92.7) 0.91
P2Y12 inhibitor 36 (94.7) 74 (90.2) 0.41
Vitamin K antagonist 7 (18.4) 8 (9.8) 0.18
Statin 35 (92.1) 79 (96.3) 0.32
Beta-blocker 36 (94.7) 69 (84.1) 0.10
ACE inhibitor or ARB 34 (89.5) 65 (79.3) 0.17
ACE: angiotensin converting enzyme; ARB: angiotensin II receptor blocker;
CABG: coronary artery bypass grafting; CKmax: maximum creatine kinase dur-
ing the index admission; NSTEMI: non-ST-elevation myocardial infarction; PCI:
percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction;
troponin ax: maximum troponin value during the index admission; UAP:
unstable angina pectoris.
Continuous variables are presented as median (25th–75th percentile).
Categorical variables are presented as number (percentage).
aThe first blood sample >7 days was taken at a median (25th–75th percent-
ile) of 24 (16–34) days after the index ACS.
Table 3. Difference in protein biomarker serum level between cases and con-
trols 30 days.
Protein (NPX) Coefficient 95%CI p Value
ADAM-TS13 0.079 (–0.093 to 0.25) 0.36
ADM 0.36 (0.015 to 0.70) 0.041
ACE2 0.69 (0.18 to 1.20) 0.009
CXCL1 1.00 (0.38 to 1.61) 0.002
CEACAM8 0.38 (–0.070 to 0.83) 0.096
CTSL1 0.21 (–0.10 to 0.52) 0.18
HO-1 0.14 (–0.19 to 0.47) 0.39
IL-1ra 0.11 (–0.49 to 0.71) 0.72
IL1RL2 0.046 (–0.22 to 0.31) 0.73
IL-17D 0.23 (0.029 to 0.43) 0.026
IL-27 0.36 (0.093 to 0.62) 0.009
IL-4RA 0.48 (0.16 to 0.80) 0.004
LOX-1 0.16 (–0.23 to 0.54) 0.42
LPL 0.12 (–0.42 to 0.17) 0.40
IgG Fc receptor II-b 0.17 (–0.25 to 0.60) 0.42
MARCO 0.086 (–0.069 to 0.24) 0.27
hOSCAR 0.15 (–0.040 to 0.33) 0.12
PTX3 0.34 (–0.13 to 0.80) 0.15
PIgR 0.040 (–0.032 to 0.11) 0.27
IL16 0.21 (–0.14 to 0.56) 0.23
PD-L2 0.21 (–0.010 to 0.42) 0.061
RAGE 0.40 (0.12 to 0.67) 0.006
CD84 0.64 (0.25 to 1.03) 0.002
SPON2 0.14 (0.026 to 0.25) 0.017
CD4 0.19 (–0.024 to 0.41) 0.080
TF 0.14 (–0.049 to 0.33) 0.14
TRAIL-R2 0.29 (–0.041 to 0.62) 0.084
TNFRSF10A 0.41 (0.20 to 0.62) 0.0004
TNFRSF13B 0.096 (–0.23 to 0.43) 0.56
ACS: acute coronary syndrome; CI: confidence interval; NPX: Normalized
Protein eXpression.
For every protein biomarker, the difference in serum level between cases and
controls is expressed in a relative arbitrary unit on the log 2 scale. Thus, an
increase or decrease of one NPX corresponds with a doubling or a halving of
the protein serum level.
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cases and controls with the Mann–Whitney U test.
Categorical baseline characteristics are presented as numbers
with percentages and were compared between cases and
controls with the Chi-square test.
Linear mixed-effects models were fitted for every protein
(dependent). To allow individual variation per patient, random
intercepts were included in the models. Likelihood ratio tests
and F tests were used for hypothesis testing, and model
assumptions were checked by visual examination of the resid-
uals. To account for the 29 proteins tested, correction for mul-
tiple testing was applied (p¼ 0.003) (Li and Ji 2005). The
corrected significance level was calculated using the matrix
spectral decomposition method, a correction method used in
‘omics’ studies to account for the number of independent
Figure 2. The temporal pattern of CD84, TNFRSF10A and CXCL1. NPX: Normalized Protein eXpression.
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performed tests (Nyholt 2004, Li and Ji 2005). All statistical tests
were two-tailed. R statistical software (version 3.4.0) was used
for statistical analyses, in particular the package nlme (https://
cran.r-project.org/web/packages/nlme/index.html).
Results
Baseline characteristics
Mean age was 66 ± 12 years and 80% were men. Presentation,
initial treatment, cardiovascular risk factors and medication at
first blood sample (baseline) were similar for cases and
matched controls (Table 2). Thus, matching was successful.
Biomarker pattern within first 30 days post-ACS
Fifteen cases experienced a recurrent event within the first
30 days of follow-up. After correction for multiple testing,
the serum level of CXCL1 in the first 30 days was 1.00 NPX
(95% confidence interval (CI) 0.38–1.61) higher in cases than
in their matching controls, which corresponds to a doubling
of the CXCL1 serum level in cases. The serum levels of CD84
and TNFRSF10A were also significantly higher in cases than
in their matching controls with a difference in these serum
levels of 0.64 NPX (95%CI 0.25–1.03) and 0.41 NPX (95%CI
0.20–0.62), respectively (Table 3, Figure 2 left-hand panel).
Biomarker pattern after 30 days
Twenty nine cases experienced their recurrent event
between 30 days and one year following their initial ACS.
Prior to the recurrent coronary event in the 30-day to one-
year period, serum levels of all studied protein biomarkers
stabilized in cases and matched controls to indistinctive
serum levels (Table 4). Hence, we found no significant diver-
gent protein biomarker patterns between so-called late cases
and matched controls. In particular, no (steady) increase was
observed prior to the repeat event.
Since we did find significant divergent protein biomarker
patterns between early cases and matched controls, we com-
pared protein biomarker serum levels of 30-day cases with
those of >30-day cases as a post hoc analysis in the first
30 days post index-ACS (Table 5). Overall, most protein bio-
marker serum levels appeared to be higher in early cases.
Discussion
This study assessed the temporal pattern of 29 immune and
inflammatory proteins in post-ACS patients. Serum levels of
CXCL1, CD84 and TNFRSF10A showed to be significantly
higher in cases than in matched controls prior to their recur-
rent coronary event within 30 days after the index ACS. After
the first 30 days of follow-up, none of the studied protein
biomarkers had detectable divergent serum levels in cases
and their matched controls.
Table 4. Protein biomarker serum levels in relation to time post index ACS.
Median maximum value 7 daysa
Patient-level mean value
30 daysb
Patient-level mean value
>30 daysb
Protein (NPX) Cases Controls Cases Controls Cases Controls
ADAM-TS13 5.22 (5.02–5.47) 5.19 (4.94–5.31) 5.17 ± 0.32 5.19 ± 0.27 5.20 ± 0.30 5.26 ± 0.31
ADM 7.53 (7.10–8.01) 7.21 (6.75–7.54) 7.36 ± 0.50 7.06 ± 0.55 7.18 ± 0.54 6.99 ± 0.55
ACE2 4.24 (3.95–5.06) 3.95 (3.56–4.29) 4.27 ± 0.92 4.00 ± 0.79 4.21 ± 0.62 4.18 ± 0.86
CXCL1 9.42 (8.76–9.98) 8.68 (7.86–9.22) 8.95 ± 1.07 8.67 ± 1.22 8.46 ± 1.29 8.76 ± 1.22
CEACAM8 3.98 (3.52–4.25) 3.64 (3.09–4.12) 3.76 ± 0.79 3.54 ± 0.65 3.35 ± 0.61 3.30 ± 0.61
CTSL1 5.39 (5.06–5.57) 5.17 (4.85–5.48) 5.30 ± 0.59 5.15 ± 0.49 5.07 ± 0.44 5.02 ± 0.50
HO-1 13.00 (12.63–13.25) 12.79 (12.26–13.20) 12.71 ± 0.50 12.77 ± 0.54 12.55 ± 0.34 12.77 ± 0.52
IL-1ra 7.56 (6.60–8.07) 6.94 (6.44–7.52) 7.11 ± 0.78 7.04 ± 0.92 6.75 ± 0.51 6.81 ± 0.78
IL1RL2 3.13 (2.67–3.47) 3.07 (2.62–3.30) 3.07 ± 0.41 3.07 ± 0.43 3.14 ± 0.34 3.07 ± 0.44
IL-17D 2.49 (2.34–2.71) 2.18 (2.00–2.53) 2.34 ± 0.35 2.22 ± 0.31 2.26 ± 0.22 2.25 ± 0.36
IL-27 3.20 (2.69–3.55) 2.80 (2.51–3.13) 3.05 ± 0.55 2.85 ± 0.42 2.87 ± 0.35 2.79 ± 0.29
IL-4RA 2.21 (1.84–2.91) 1.86 (1.71–2.16) 2.22 ± 0.66 1.88 ± 0.30 1.81 ± 0.26 1.82 ± 0.32
LOX-1 6.33 (5.70–6.96) 5.99 (5.55–6.50) 6.08 ± 0.69 6.03 ± 0.62 5.85 ± 0.49 5.92 ± 0.50
LPL 9.26 (8.67–9.73) 9.09 (8.89–9.67) 9.23 ± 0.50 9.30 ± 0.52 9.40 ± 0.53 9.34 ± 0.49
IgG Fc receptor II-b 3.06 (2.62–3.50) 2.96 (2.43–3.39) 3.01 ± 0.73 2.94 ± 0.70 2.97 ± 0.85 2.88 ± 0.75
MARCO 5.00 (4.79–5.13) 4.93 (4.75–5.19) 4.98 ± 0.22 4.98 ± 0.29 4.99 ± 0.26 5.02 ± 0.29
hOSCAR 10.60 (10.42–10.78) 10.43 (10.19–10.77) 10.58 ± 0.30 10.42 ± 0.35 10.51 ± 0.31 10.40 ± 0.35
PTX3 3.96 (2.96–4.47) 3.38 (2.98–4.06) 3.43 ± 0.82 3.31 ± 0.68 3.03 ± 0.56 2.91 ± 0.51
PIgR 7.25 (7.10–7.33) 7.17 (7.07–7.27) 7.18 ± 0.17 7.17 ± 0.14 7.20 ± 0.18 7.19 ± 0.15
IL16 5.41 (5.18–5.82) 5.23 (4.85–5.54) 5.30 ± 0.48 5.18 ± 0.60 5.33 ± 0.37 5.15 ± 0.52
PD-L2 2.64 (2.30–3.06) 2.44 (2.16–2.74) 2.64 ± 0.44 2.50 ± 0.38 2.65 ± 0.48 2.60 ± 0.37
RAGE 5.57 (5.31–5.92) 5.30 (4.98–5.51) 5.45 ± 0.50 5.14 ± 0.39 5.30 ± 0.51 5.13 ± 0.43
CD84 5.54 (4.86–5.80) 4.93 (4.53–5.33) 5.34 ± 0.62 5.09 ± 0.63 5.17 ± 0.67 5.24 ± 0.65
SPON2 10.28 (10.11–10.43) 10.13 (9.95–10.26) 10.18 ± 0.26 10.09 ± 0.24 10.17 ± 0.21 10.11 ± 0.26
CD4 2.99 (2.48–3.25) 2.74 (2.45–3.02) 2.83 ± 0.38 2.79 ± 0.46 2.87 ± 0.40 2.85 ± 0.46
TF 5.60 (5.48–5.85) 5.55 (5.35–5.78) 5.55 ± 0.31 5.54 ± 0.32 5.59 ± 0.37 5.58 ± 0.36
TRAIL-R2 5.79 (5.48–6.42) 5.65 (5.34–5.93) 5.69 ± 0.60 5.60 ± 1.04 5.61 ± 0.67 5.47 ± 1.03
TNFRSF10A 2.80 (2.50–3.32) 2.48 (2.15–2.78) 2.69 ± 0.44 2.46 ± 0.40 2.50 ± 0.39 2.45 ± 0.36
TNFRSF13B 7.47 (7.33–7.86) 7.55 (7.05–7.85) 7.72 ± 0.88 7.60 ± 0.54 7.89 ± 1.05 7.71 ± 0.59
NPX: Normalized Protein eXpression.
Blood samples in the time windows 0–7, 8–30 and 30–365 days after the index ACS were available for 23, 32, 28 cases and for 44, 67, 70 controls.
aMedian (25th–75th percentile) value of the patient-level maximum.
bMean ± standard deviation value of the patient-level mean.
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CXCL1 is a cytokine that attracts neutrophils by chemo-
taxis and stimulates monocyte arrest (Dusi et al. 2016).
Oxidized LDL and wall shear stress on endothelial cells have
been shown to induce the expression of CXCL1 (Hagiwara
et al. 1998, Zhou et al. 2011). Subsequently, CXCL1 stimulates
monocyte adhesion to the endothelial wall (Breland et al.
2008, Papadopoulou et al. 2008). These monocytes migrate
into the endothelial wall and stimulate the accumulation of
macrophages. Eventually, this process promotes atheroscler-
otic plaque formation and instability and is therefore a key
process in pathological atherosclerosis. Since we found
higher serum levels of CXCL1 in early cases, a possible mech-
anism may be that CXCL1 is upregulated due to the index
ACS, but subsequently also promotes early recurrent events
by inducing atherosclerotic plaque instability.
CD84 is a signalling lymphocyte activation molecule
(SLAM) and is expressed on platelets. It has been described
that during thrombus formation, CD84 is triggered upon
platelet aggregation and advances thrombus stability (Nanda
et al. 2005). Since disproportional thrombus formation may
cause arterial occlusion, CD84 may be of interest as a bio-
marker for coronary events. However, little research has been
conducted on CD84 and its association with CVD. One previ-
ous study has identified CD84 to be associated with adverse
outcome in Kawasaki disease coronary arteriopathy (Reindel
et al. 2014). In this study, CD84 was found to be highly
expressed in inflamed endothelium tissue of the coronary
arteries of patients who developed adverse outcome and
was suggested to play an important role in the pathogenesis
of arterial thrombosis (Reindel et al. 2014). Our study found
higher CD84 serum levels in post-ACS patients who devel-
oped early recurrent events. Potentially, CD84 upregulation is
initiated by the index ACS and, subsequently, promotes dis-
proportional thrombus formation causing early recurrent
ACS. Further research should establish whether CD84 serum
levels may be used to identify patients who will develop an
early recurrent coronary event and who will not.
TNFRSF10A, a receptor for TNFSF10/TRAIL, is a member of
the TNF-receptor superfamily and modulates apoptosis and
proliferation of vascular smooth muscle cells (Pan et al. 1997,
Kavurma et al. 2008). Since these processes may be beneficial
as well as disadvantageous for atherosclerosis, depending on
the stage of an atherosclerotic lesion, there is still an
ongoing debate as to whether TNFRSF10A and its ligand
may be used as a marker for progression or regression of
atherosclerosis (Forde et al. 2016). Our study found higher
serum levels of TNFRSF10A in patients who developed an
early recurrent cardiac event. Potentially, higher TNFSRF10A
serum levels induce excessive proliferation of vascular
smooth muscle cells after the index ACS which may lead to
new coronary stenosis (Kavurma and Bennett 2008).
Our study shows that CXCL1, CD84 and TNFRSF10A serum
levels were elevated in post-ACS patients who experienced
an early repeat coronary event. Nonetheless, we did not find
divergent protein biomarker serum levels in post-ACS
patients who experienced a late repeat coronary event (i.e.
in the 30-day to one-year time-window). One may argue that
differences in serum levels between cases and controls may
be smaller in the long-term and our study lacked power to
reveal these. We designed the current study as an initial ana-
lysis and did not quantify all collected blood samples in
BIOMArCS, since we intended – depending on the first
results – to assess more blood samples after our first analysis
to expand the number of repeated biomarker measurements.
However, since we did find associations in early cases, and
our study did not lack power to reveal these associations, we
conclude that the 29 protein biomarkers we studied may not
be associated with the development of recurrent coronary
events in late cases. Apparently, the index ACS triggers
short-term upregulation of CXCL1, CD84 and TNFRSF10A,
which may play a role in the development of early recurrent
coronary events.
For our protein measurements, we used Olink’s PEA tech-
nique. This PEA technique enables an effective assessment of
blood samples with a rapid high-throughput analysis of high
sensitivity and specificity. However, although PEA is a prom-
ising technique, improvements are warranted to assure clin-
ical valid and reproducible measurements. In addition to the
technical challenges, one should consider that other factors
related to biobank-sampling, i.e. blood sample collection and
repeated freezing and thawing of collected blood samples
influence the reproducibility of protein measurements.
Studying the behaviour over time of immune and inflamma-
tory proteins in patients with CVD prior to a (recurrent) cor-
onary event may provide new insights on modulators of
pathological atherosclerosis. However, current research
remains exploratory. Technical improvements are required to
assess whether immune and inflammatory proteins can be
Table 5. Protein biomarker serum levels in the first 30 days for cases only.
Protein (NPX) Early casesa Late casesa p Value
ADAM-TS13 5.25 ± 0.30 5.10 ± 0.34 0.20
ADM 7.53 ± 0.50 7.21 ± 0.45 0.067
ACE2 4.64 ± 1.03 3.94 ± 0.70 0.032
CXCL1 9.45 ± 0.69 8.51 ± 1.16 0.010
CEACAM8 3.98 ± 0.72 3.56 ± 0.82 0.13
CTSL1 5.42 ± 0.59 5.20 ± 0.59 0.30
HO-1 12.91 ± 0.49 12.53 ± 0.45 0.028
IL-1ra 7.23 ± 0.84 7.00 ± 0.73 0.42
IL1RL2 2.99 ± 0.43 3.14 ± 0.40 0.33
IL-17D 2.48 ± 0.37 2.22 ± 0.28 0.032
IL-27 3.26 ± 0.59 2.87 ± 0.45 0.045
IL-4RA 2.44 ± 0.75 2.03 ± 0.51 0.079
LOX-1 6.11 ± 0.48 6.06 ± 0.84 0.83
LPL 9.20 ± 0.51 9.25 ± 0.51 0.77
IgG Fc receptor II-b 2.97 ± 0.74 3.05 ± 0.74 0.77
MARCO 5.02 ± 0.21 4.95 ± 0.23 0.36
hOSCAR 10.62 ± 0.23 10.54 ± 0.35 0.48
PTX3 3.64 ± 0.93 3.24 ± 0.68 0.18
PIgR 7.23 ± 0.11 7.14 ± 0.20 0.10
IL16 5.34 ± 0.42 5.27 ± 0.54 0.68
PD-L2 2.70 ± 0.35 2.58 ± 0.51 0.45
RAGE 5.65 ± 0.47 5.28 ± 0.47 0.036
CD84 5.58 ± 0.63 5.13 ± 0.55 0.039
SPON2 10.28 ± 0.21 10.08 ± 0.27 0.031
CD4 2.95 ± 0.33 2.72 ± 0.39 0.079
TF 5.69 ± 0.24 5.43 ± 0.31 0.011
TRAIL-R2 5.88 ± 0.64 5.53 ± 0.53 0.10
TNFRSF10A 2.92 ± 0.41 2.48 ± 0.36 0.003
TNFRSF13B 7.66 ± 0.40 7.78 ± 1.17 0.71
NPX: Normalized Protein eXpression.
Blood samples 30 days after the index ACS were available for 15 early cases
and 17 late cases.
aPatient-level mean value ± standard deviation.
6 M. M. VROEGINDEWEY ET AL.
used in clinical practice and may contribute to established
clinical tools for disease detection and prognosis. Finally, the
proposed mechanisms through which the biomarkers may
be pathophysiologically related to the repeat ACS are
hypothesis generating.
Conclusions
Among 29 immune and inflammatory proteins on the Olink
platform, CXCL1, CD84 and TNFRSF10A were associated with
early repeat coronary events in patients who experienced an
ACS. Further research should assess whether CXCL1, CD84 and
TNFRSF10A can actually be used to discriminate between
patients who will experience an early repeat coronary event
after an initial ACS admission, and patients who will not.
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